Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting

Wassim Kassouf¹, Armen Aprikian¹, Fred Saad², Rodney H Breau³, Girish Kulkarni⁴, David M Guttman⁵, Ken Bagshaw⁵, Jonathan Izawa⁶, Libni Eapen⁷, Adrian Fairey⁸, Alan So⁹, Scott North¹⁰, Ricardo Rendon¹¹, Srikala S Sridhar¹², Fadi Brimo¹³, Peter Chung¹⁴, Darrel Drachenberg¹⁵, Yves Fradet¹⁶, Niels Jacobsen⁸, Chris Morash³, Bobby Shayegan¹⁷, Geoffrey Gotto¹⁸, Alex Zlotta⁴, Neil Fleshner⁴, D Robert Siemens¹⁹, Peter C Black⁹

Affiliations

¹ Department of Urology, McGill University Health Centre, Montreal, QC.
² Division of Urology, University of Montreal, Montreal, QC.
³ Division of Urology, University of Ottawa, Ottawa, ON.
⁴ Departments of Surgery (Urology), Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON.
⁵ Patient representatives, Bladder Cancer Canada.
⁶ Division of Urology, Western University, London, ON.
⁷ Division of Radiation Oncology, University of Ottawa, Ottawa, ON.
⁸ Division of Urology, University of Alberta, Edmonton, AB.
⁹ Department of Urologic Sciences, University of British Columbia, Vancouver, BC.
¹⁰ Division of Medical Oncology, University of Alberta, Edmonton, AB.
¹¹ Division of Urology, Dalhousie University, Halifax, NS.
¹² Departments of Medical Oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON.
¹³ Department of Pathology, McGill University Health Centre, Montreal, QC.
¹⁴ Departments of Radiation Oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON.
¹⁵ Division of Urology, University of Manitoba, Winnipeg, MB.
¹⁶ Division of Urology, Laval University, Quebec City, QC.
¹⁷ Division of Urology, McMaster University, Hamilton, ON.
¹⁸ Division of Urology, University of Calgary, Calgary, AB.
¹⁹ Department of Urology, Queen's University, Kingston, ON; Canada.

PMID: 29603921
PMCID: PMC6118052
DOI: 10.5489/cuaj.5246

Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting

Wassim Kassouf et al. Can Urol Assoc J. 2018 Jul.

. 2018 Jul;12(7):E281-E297.

doi: 10.5489/cuaj.5246. Epub 2018 Mar 19.

Authors

Affiliations

¹ Department of Urology, McGill University Health Centre, Montreal, QC.
² Division of Urology, University of Montreal, Montreal, QC.
³ Division of Urology, University of Ottawa, Ottawa, ON.
⁴ Departments of Surgery (Urology), Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON.
⁵ Patient representatives, Bladder Cancer Canada.
⁶ Division of Urology, Western University, London, ON.
⁷ Division of Radiation Oncology, University of Ottawa, Ottawa, ON.
⁸ Division of Urology, University of Alberta, Edmonton, AB.
⁹ Department of Urologic Sciences, University of British Columbia, Vancouver, BC.
¹⁰ Division of Medical Oncology, University of Alberta, Edmonton, AB.
¹¹ Division of Urology, Dalhousie University, Halifax, NS.
¹² Departments of Medical Oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON.
¹³ Department of Pathology, McGill University Health Centre, Montreal, QC.
¹⁴ Departments of Radiation Oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON.
¹⁵ Division of Urology, University of Manitoba, Winnipeg, MB.
¹⁶ Division of Urology, Laval University, Quebec City, QC.
¹⁷ Division of Urology, McMaster University, Hamilton, ON.
¹⁸ Division of Urology, University of Calgary, Calgary, AB.
¹⁹ Department of Urology, Queen's University, Kingston, ON; Canada.

PMID: 29603921
PMCID: PMC6118052
DOI: 10.5489/cuaj.5246

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Kassouf has received grants/honoraria from Amgen, Astellas, and Janssen. Dr. Aprikian has received grants/honoraria from Abbvie, Amgen, Astellas, and Janssen; and has participated in clinical trials supported by Astellas. Dr. Saad has attended advisory boards for and received payment/honoraria from AbbVie, Amgen Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Amgen Astellas, Bayer, Janssen, and Sanofi. Dr. Izawa has received grants/honoraria from Abbott, AstraZeneca, Astellas, Janssen, Sanofi, and Pfizer. Dr. Eapen has received grants/honoraria from Abbott and AstraZeneca; and has participated in numerous clinical trials. Dr. Fairey has received speaker honoraria from J&J and Roche. Dr. So has been a speaker for Amgen, Astellas, and Janssen. Dr. North has attended advisory boards for Astellas; has received grants/honoraria from Astellas, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Janssen, and Sanofi. Dr. Rendon has attended advisory boards and has been a speaker for Amgen, Astellas, Ferring, and Janssen. Dr. Sridhar has attended advisory boards for Astellas; has received grants/honoraria from Astellas, Janssen, and Sanofi; and has participated in clinical trials for Agenisys, Imclone, OGX, Roche, and Sanofi Aventis. Dr. Chung has received grants/honoraria from Sanofi. Dr. Fradet has attended advisory boards for Amgen, Astellas, AstraZeneca, DiagnoCure, and Janssen; has received grants/honoraria from Amgen, Astellas, AstraZeneca, GammaDynacare, and Janssen; and has participated in clinical trials supported by Abbott. Dr. Morash has attended advisory boards for AbbVie, Astellas, Ferring, Janssen, and Sanofi. Dr. Shayegan has received grants/honoraria from AbbVie, Astellas, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas and Janssen. Dr. Gotto has attended advisory boards for Amgen, Astellas, and Janssen; has received honoraria from Amgen, Astellas, Janssen, and Novartis; and has participated in the clinical trials SPARTAN, ENZAMET, and COSMiC. Dr. Siemens has participated in clinical trials supported by Amgen, Astellas, Ferring, and Janssen. Dr. Black has attended advisory boards for AbbVie, Amgen, Astellas, Biocancell, Cubist, Janssen, Novartis, and Sitka; has been a speaker for AbbVie, Janssen, Ferring, Novartis, and Red Leaf Medical; has received grants/honoraria from Pendopharm; has participated in clinical trials supported by Amgen, Astellas, Ferring, Janssen, and Roche; and has received research funding from GenomeDx, iProgen, Lilly, and New B Innovation. The remaining authors declare no competing financial or personal interests.

Figures

**Fig. 1**
Conceptual framework of a Canadian Bladder Cancer Research Network. CAGMO: Canadian Association of Genitourinary Medical Oncologists; CARO: Canadian Association of Radiation Oncology; CBCIS: Canadian Bladder Cancer Information System; CCTG: Canadian Cancer Trials Group; CUOG: Canadian Urologic Oncology Group; GUROC: Genitourinary Radiation Oncologists of Canada.

See this image and copyright information in PMC

References

1. Kassouf W, Aprikian A, Black P, et al. Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Can Urol Assoc J. 2016;10:E46–80. doi: 10.5489/cuaj.3583. - DOI - PMC - PubMed
1. Khare SR, Aprikian A, Black P, et al. Quality indicators in the management of bladder cancer: A modified Delphi study. Urol Oncol. 2017;35:328–34. doi: 10.1016/j.urolonc.2016.12.003. - DOI - PubMed
1. Yafi FA, Aprikian AG, Tanguay S, et al. Patients with microscopic and gross hematuria: Practice and referral patterns among primary care physicians in a universal healthcare system. Can Urol Assoc J. 2011;5:97–101. doi: 10.5489/cuaj.10059. - DOI - PMC - PubMed
1. Santos F, Dragomir A, Kassouf W, et al. Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer. Curr Oncol. 2015;22:e20–6. doi: 10.3747/co.22.2052. - DOI - PMC - PubMed
1. Santos F, Dragomir A, Kassouf W, et al. Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec, Canada: A population-based study. BJU Int. 2015;115:389–96. doi: 10.1111/bju.12742. - DOI - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting

Affiliations

Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting

Authors

Affiliations

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources

Other Literature Sources